Medical Sciences Post-graduate Program, Department of Clinical Medicine, Universidade Federal do Ceará, Brazil.
Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Ceara, Fortaleza, Ceara, Brazil.
Respir Med. 2018 Jan;134:103-109. doi: 10.1016/j.rmed.2017.12.005. Epub 2017 Dec 7.
Hemodialysis (HD) patients have altered pulmonary function and this is associated with impaired endothelial function and cardiovascular events. Respiratory muscle training (RMT) has the potential to improve cardiovascular outcomes in patients undergoing maintenance HD. Here, we evaluated the effects of RMT on endothelium/glycocalyx, oxidative stress biomarkers and pulmonary function test in HD patients.
This is a randomized controlled clinical trial including 41 patients undergoing thrice-weekly maintenance HD. Patients were randomly assigned at a 2:1 ratio to receive or not RMT during HD sessions for 8 weeks. Main outcomes were changes in levels of the biomarkers related to endothelium activation (vascular cell adhesion molecule 1, VCAM-1, and intercellular adhesion molecule 1, ICAM-1), glycocalyx derangement (syndecan-1), aberrant angiogenesis (angiopoietin-2) and oxidative stress (malondialdehyde) compared to baseline. Also, maximal inspiratory/expiratory pressure (MIP, MEP), Forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) were evaluated. Other outcomes included changes in functional capacity and pulmonary function test. We also performed a post-hoc analysis of plasma endothelin-1 levels.
Of 56 randomly assigned patients, 41 were included in the primary final analyses. RMT increased all pulmonary function parameters evaluated and significantly reduced plasma syndecan-1 levels at 8 weeks compared to placebo (between-group difference: -84.5; 95% CI, -148.1 to -20.9). Also, there was a reduction in plasma levels of angiopoietin-2 (between-group difference: -0.48; 95% CI, -1.03 to -0.097). Moreover, there was a significant reduction in mean blood pressure at rest (between-group difference: -12.2; 95%CI, -17.8 to -6.6) associated with a reduction in endothelin-1 levels (between-group difference: -0.164; 95% CI, -0.293 to -0.034). There was no difference regarding biomarkers of endothelial activation or oxidative stress.
A short-term RMT program ameliorate FVC, FEV1 and reduces syndecan-1 and angiopoietin-2 biomarker levels. Finally, better blood pressure control was attained during training and it was associated with a reduction in endothelin-1 levels.
血液透析(HD)患者的肺功能发生改变,这与内皮功能障碍和心血管事件有关。呼吸肌训练(RMT)有可能改善接受维持性 HD 治疗的患者的心血管结局。在这里,我们评估了 RMT 对 HD 患者内皮/糖萼、氧化应激生物标志物和肺功能测试的影响。
这是一项包括 41 名接受每周三次维持性 HD 的患者的随机对照临床试验。患者按 2:1 的比例随机分配接受或不接受 HD 治疗期间的 RMT,持续 8 周。主要结局是与内皮细胞激活(血管细胞黏附分子 1、VCAM-1 和细胞间黏附分子 1、ICAM-1)、糖萼紊乱(连接蛋白-1)、异常血管生成(血管生成素 2)和氧化应激(丙二醛)相关的生物标志物水平与基线相比的变化。此外,还评估了最大吸气/呼气压力(MIP、MEP)、用力肺活量(FVC)和第 1 秒用力呼气量(FEV1)。其他结局包括功能能力和肺功能测试的变化。我们还对血浆内皮素-1 水平进行了事后分析。
在随机分配的 56 名患者中,有 41 名患者纳入主要的最终分析。与安慰剂相比,RMT 增加了所有评估的肺功能参数,并在 8 周时显著降低了血浆连接蛋白-1 水平(组间差异:-84.5;95%CI,-148.1 至-20.9)。此外,血浆血管生成素-2 水平也降低(组间差异:-0.48;95%CI,-1.03 至-0.097)。此外,休息时平均血压显著降低(组间差异:-12.2;95%CI,-17.8 至-6.6),同时内皮素-1 水平降低(组间差异:-0.164;95%CI,-0.293 至-0.034)。内皮激活或氧化应激的生物标志物无差异。
短期 RMT 方案可改善 FVC、FEV1,并降低连接蛋白-1 和血管生成素-2 生物标志物水平。最后,在训练过程中实现了更好的血压控制,这与内皮素-1 水平的降低有关。